Introduction Demographics Clinical features Diagnosis Treatment
NOMID and CINCA are alternative acronyms for the same disorder.
NOMID/CINCA (MIM 607115) is the most severe and rarest form of cryopyrin-associated periodic syndrome (CAPS). Although usually due to a single gene mutation, it is rarely, if ever, inherited as it causes major disabilities and is often fatal before adult life. It is called CINCA in Europe (where the syndrome was first described and studied in detail) and NOMID in the USA.
NOMID/CINCA is a very rare autoinflammatory syndrome, presenting at or within days of birth. Signs in the brain may be detected on prenatal ultrasound before birth in severe cases. Birth is premature in one-third of cases, and birth weight may be small for dates.
NOMID/CINCA is an autosomal dominant condition meaning only a single copy of the defective gene is required to cause the clinical syndrome. The child of a sufferer would have a 50% chance of inheriting the condition. However, it is not usually familial as it is either fatal before adult life or results in severe disabilities. Therefore nearly all reported cases have resulted from spontaneous mutations. This may change with successful treatment now minimising neurological disability.
Mutations in the NLRP3 gene are commonly identified in NOMID/CINCA, therefore linking it with Muckle-Wells syndrome and familial cold associated syndrome. Some mutations, such as Y570C, Y570F, F309S and F523L, are unique to severe NOMID/CINCA. Mild clinical features of NOMID/CINCA are sometimes observed in patients with Muckle-Wells syndrome. Different overlap features can be seen even within one family. However the severe clinical features of NOMID/CINCA have never been reported in families with milder forms of CAPS.
NOMID/CINCA is likely to be a heterogeneous (i.e. due to more than one genetic defect) condition as 40% of cases do not have an identifiable mutation in the NLRP3 gene. There is, however, no difference in response to treatment with anakinra between those with or without the NLRP3 mutations. The mechanism of disease development is likely to involve overstimulation of the interleukin-1beta receptor in all cases.
The clinical features of NOMID/CINCA that differentiate it from the other forms of CAPS include presentation at birth or soon after, severe unique joint changes and chronic aseptic meningitis which results in profound developmental delay and significant disability. As in all forms of CAPS, symptoms include skin rash, fever and inflammation of the eyes.
The symptoms of NOMID/CINCA tend to be constant, rather than episodic, with intermittent flares in activity. Clinical features of NOMID/CINCA are shown in the table below.
Symptom |
Description |
|
|---|---|---|
Fever |
|
|
Skin rash |
|
|
Joint changes |
Early onset in the first year after birth:
|
|
Later onset:
|
||
Chronic aseptic meningitis:
Intellectual disability (50%)
|
||
Neurological |
Hearing loss:
|
|
Eye problems:
|
||
Physical appearance |
|
|
Other |
|
|
20% die before reaching adult life, due to infection, vasculitis and amyloidosis.
NOMID-CINCA is characterised by the clinical triad of skin, joint and neurological inflammation presenting at or around the time of birth.
Clinical clues that should raise particular suspicion of the diagnosis in a child are:
The table below describes the results of investigations.
Test |
Findings |
|
|---|---|---|
Blood tests |
|
|
X-rays |
|
|
CSF |
|
|
Skin biopsy |
|
|
Audiometry |
|
|
Ophthalmologic assessment |
|
|
CT scan |
|
|
MRI with gadolinium |
|
|
EEG |
|
|
Anakinra is a biologic agent. It is is a recombinant interleukin-1 receptor antagonist and the treatment of choice for NOMID/CINCA. It is given as a daily subcutaneous injection, dose range 1-10mg/kg/d. Very young children appear to require a much higher dose per kg (6-10mg/kg/d) to control symptoms and inflammatory markers than older children or adults (1-3 mg/kg/d). It should be started as early in life as possible to minimise irreversible neurological complications. It is likely treatment will be continued for life. So far studies have been reported with up to 42 months of continuous treatment. Treatment has been started as young as 3 months of age.
Two large prospective case series have been reported, one involving 18 patients and the second 10, including two infants.
Improvement has been reported in:
But no improvement is seen in the bone changes which can continue to progress. Consequences of secondary amyloidosis, deafness, visual impairment, intellectual disability or existing developmental delay can or do persist, remaining stable or showing further progression. Proteinuria may improve but kidney impairment may be stable. Evidence of persistent CNS inflammation may be detected in CSF as increased protein and/or white cells and on MRI. Approximately one-third showed partial improvement in existing hearing loss on audiograms, but deterioration was noted in 17% in one series.
In the first series, all 18 patients showed clearance of the rash within 3 days, and complete remission of inflammatory changes within 6 months. Relapse occurred within 5 days of ceasing anakinra. In the more recent series, all 10 patients had complete clinical remission of fever, rash, joint and muscle pain within 24 hours of the first injection. Improvement was, in all but one patient, maintained throughout treatment over 2-3.5 years. The two very young patients (treatment started at 3 and 4 months of age) however showed recurrence of symptoms 6-8 hours after low-dose (1mg/kg/d) injection and required escalating split doses. One continued to develop occasional skin rashes associated with viral infections despite a dose of 10mg/kg/d. Persistence of headaches correlated with the presence of papilloedema and responded to increased dosages.
In the prospective study of 18 patients with NOMID/CINCA, local injection site reactions were the commonest adverse event, with an increase in upper respiratory tract infections. In the second series of 10 patients, injection site reactions only were reported. Very young chldren are at risk of developing pneumococcal infection due to the very high doses required and their poor immune response to encapsulated bacteria. All patients should be immunised against Streptococcus pneumoniae and Haemophilus influenzae before starting therapy and is is suggested very young children should be prescribed prophylactic antibiotics.
Anakinra has a major beneficial impact on the quality of life of patients with NOMID/CINCA. If started early in life, anakinra may prevent the disability caused by joint changes and neurological inflammation, however longer followup is required to confirm this impression.
Note: anakinra is not registered or subsidised in New Zealand (March 2011). In other countries such as the USA and Europe, its registered indication is rheumatoid arthritis.
